Development, opportunities, and challenges of siRNA nucleic acid drugs
Small interfering RNA (siRNA) drugs were first proposed in 1999. They have reached the market for administration to patients after more than 20 years of development. The US Food and Drug Administration has approved six siRNA drugs in recent years: patisiran, givosiran, lumasiran, vutrisiran, inclisi...
Saved in:
Main Authors: | Bowen Xiao, Shaopeng Wang, Yu Pan, Wenjun Zhi, Chensheng Gu, Tao Guo, Jiaqi Zhai, Chenxu Li, Yong Q. Chen, Rong Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2025-03-01
|
Series: | Molecular Therapy: Nucleic Acids |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S216225312400324X |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Flow rate modulates focused ultrasound-mediated vascular delivery of microRNA
by: Stephanie He, et al.
Published: (2025-03-01) -
Development of novel nucleic acid therapy aimed at directly controlling liver fibrosis
by: Tomohiro Umezu, et al.
Published: (2025-03-01) -
Scalable Manufacturing Method for Model Protein-Loaded PLGA Nanoparticles: Biocompatibility, Trafficking and Release Properties
by: Selin Akpinar Adscheid, et al.
Published: (2025-01-01) -
Cathelicidins: Opportunities and Challenges in Skin Therapeutics and Clinical Translation
by: Lenka Dzurová, et al.
Published: (2024-12-01) -
siRNA therapeutics for effective management of rheumatoid arthritis
by: Vishakha R. Chakole, et al.
Published: (2025-01-01)